ny-eso-1

NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide interacting with various HLA-DR and HLA-DP4 molecules, inducing activation of CD4+ T cells with Th1-type and Th-2/Th0-type responses when presented with these molecules.

NY-ESO-1 (157–165) peptide is a peptide derived from the NY-ESO-1 protein and has the ability to activate the immune system. It is particularly effective in individuals positive for HLA-A2, as it can be recognized by CD8+ T cells, thus triggering an immune response. The presence of NY-ESO-1 (157–165) peptide in various tumors makes it a potential target for cancer immunotherapy. This peptide is also utilized in research focusing on cancer immunotherapy.

NY-ESO-1 (157-165) peptide (TFA) is a peptide derived from the NY-ESO-1 protein. This peptide can activate the immune system and is specifically recognized by CD8+ T cells in HLA-A2 positive individuals, thereby initiating an immune response. It is expressed in various tumors and can serve as a target for tumor immunotherapy.

Baloramotide, a recombinant protein comprising 182 amino acids from NY-ESO-1, enhances the immune response to tumors [1].